Prevention of Recurrences in Dupuytren’s Contracture: Are We in the Right Side?

No abstract is available for this paper.

• Publication year

  2019

• Venue

  SN Comprehensive Clinical Medicine

• Publication date

  2019-09-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s42399-019-00138-6
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Adverse Effects of Collagenase in the Treatment of Dupuytren Disease: A Systematic Review

  2017cited by this paper
• Long-Term Effects of the Collagenase of the Bacterium Clostridium histolyticum for the Treatment of Capsular Fibrosis After Silicone Implants

  2017cited by this paper
• A novel human-like collagen hemostatic sponge with uniform morphology, good biodegradability and biocompatibility

  2017cited by this paper
• GLYCOSAMINOGLYCANS AND PROTEOGLYCANS IN PALMAR FASCIA OF PATIENTS WITH DUPUYTREN

  2016cited by this paper
• Patients’ Preferences for Treatment for Dupuytren’s Disease: A Discrete Choice Experiment

  2016cited by this paper
• Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts

  2016cited by this paper
• Collagenase From Vibrio alginolyticus Cultures

  2016cited by this paper
• Analysis of the adoption of new health technology: The case of Dupuytren's disease

  2016cited by this paper
• Matrix metalloproteinases-2/9-sensitive peptide-conjugated polymer micelles for site-specific release of drugs and enhancing tumor accumulation: preparation and in vitro and in vivo evaluation

  2016cited by this paper
• A new bromelain-based enzyme for the release of Dupuytren’s contracture

  2016cited by this paper
• Effect of P144® (Anti-TGF-β) in an “In Vivo” Human Hypertrophic Scar Model in Nude Mice

  2015cited by this paper
• Developing an animal model of Dupuytren’s disease by orthotopic transplantation of human fibroblasts into athymic rat

  2015cited by this paper
• MMP generated matrikines.

  2015cited by this paper
• Halofuginone — The Multifaceted Molecule

  2015cited by this paper
• Hyaluronan in wound healing: Rediscovering a major player

  2014cited by this paper
• High-dosage tamoxifen as neoadjuvant treatment in minimally invasive surgery for Dupuytren disease in patients with a strong predisposition toward fibrosis: a randomized controlled trial.

  2014cited by this paper
• Down‐regulation of collagen synthesis and matrix metalloproteinase expression in myofibroblasts from dupuytren nodule using adenovirus‐mediated relaxin gene therapy

  2014cited by this paper
• Identification of Histological Patterns in Clinically Affected and Unaffected Palm Regions in Dupuytren's Disease

  2014cited by this paper
• Hueston Revisited: Use of Acellular Dermal Matrix Following Fasciectomy for the Treatment of Dupuytren’s Disease

  2014cited by this paper
• Patterns of recontracture after surgical correction of Dupuytren disease.

  2013cited by this paper
• The mechanical environment in dupuytren's contracture determines cell contractility and associated MMP‐mediated matrix remodeling

  2013influential reference
• Avotermin for Scar Improvement following Scar Revision Surgery: A Randomized, Double-Blind, Within-Patient, Placebo-Controlled, Phase II Clinical Trial

  2011cited by this paper
• Expression of matrix metalloproteinases and their inhibitors in cords and nodules of patients with Dupuytren’s disease

  2009cited by this paper
• The Wound Healing Process: An Overview of the Cellular and Molecular Mechanisms

  2009cited by this paper
• Injectable collagenase clostridium histolyticum for Dupuytren's contracture.

  2009cited by this paper
• A review of fibroblast‐populated collagen lattices

  2008cited by this paper
• Antitransforming growth factor-β therapy in fibrosis: recent progress and implications for systemic sclerosis

  2008cited by this paper
• Imiquimod: a potential weapon against Dupuytren contracture.

  2006cited by this paper
• Sustained release of nanosized complexes of polyethylenimine and anti-TGF-beta 2 oligonucleotide improves the outcome of glaucoma surgery.

  2006cited by this paper
• Gelatinase A activity in Dupuytren's disease.

  2006influential reference
• Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis.

  2005cited by this paper
• Alterations in the extracellular matrix proteoglycan profile in Dupuytren's contracture affect the palmar fascia.

  2005cited by this paper
• Enhanced Dupuytren's disease fibroblast populated collagen lattice contraction is independent of endogenous active TGF-β2

  2004cited by this paper
• A Prospective Randomised Clinical Trial of the Intra-Operative Use of 5-Fluorouracil on the Outcome of Dupuytren’s Disease

  2004cited by this paper
• Tamoxifen decreases fibroblast function and downregulates TGF(beta2) in dupuytren's affected palmar fascia.

  2002cited by this paper
• Clostridial collagenase releases bioactive fragments from extracellular matrix molecules.

  1999cited by this paper
• Cells, Matrix, Growth Factors, and the Surgeon The Biology of Scarless Fetal Wound Repair

  1994cited by this paper
• Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease

  1992cited by this paper
• Spatial organization of extracellular matrix and fibroblast activity: effects of serum, transforming growth factor beta, and fibronectin.

  1990cited by this paper
• 'Firebreak' grafts in Dupuytren's contracture.

  1984cited by this paper
• Dupuytren's contracture: fibroblast contraction? An ultrastructural study.

  1972cited by this paper

• Comparative effects of various extracellular vesicle subpopulations derived from clonal mesenchymal stromal cells on cultured fibroblasts in wound healing-related process.

  2025cites this paper
• The Role of IL-6 in Skin Fibrosis and Cutaneous Wound Healing

  2020cites this paper